Navigation Links
Cocaine Use Dulls Brain's Sensitivity to Rewards
Date:11/11/2007

Findings suggest why even positive incentives don't help ease addiction

SUNDAY, Nov. 11 (HealthDay News) -- Cocaine addiction dulls the brain's sensitivity to even monetary rewards, U.S. researchers report.

A team at the U.S. Department of Energy's Brookhaven National Laboratory analyzed brain activity in 18 cocaine addicts and 18 age-matched healthy people.

The participants were outfitted with a cap of electrodes that measured brain activity as they pressed or didn't press buttons in response to visual prompts. During this task, the participants were told they could earn various amounts of money for fast and accurate performance.

The results showed that the cocaine addicts had a blunted brain response to the offer of a monetary reward.

The findings were presented Nov. 7 at the Society for Neuroscience annual meeting in San Diego.

"This altered sensitivity to reward may help explain why some drug-addicted individuals are unable to modify their drug-taking behavior, even in the face of well-understood negative consequences and/or positive incentives for behavioral change," Rita Goldstein, who runs the neuropsychoimaging lab at Brookhaven, said in a prepared statement.

In previous studies using functional magnetic resonance imaging, researchers in Goldstein's lab found similar compromised brain sensitivity to monetary reward in cocaine addicts.

"Individuals with such blunted neural and behavioral sensitivity to rewards may have a particularly difficult time responding to abstract incentives designed to motivate behavioral changes -- especially when outside of a structured treatment environment or when rewards are not readily available or clearly contingent on behavior," Goldstein said.

More information

The U.S. National Institute on Drug Abuse has more about cocaine.

'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
3. Smoking Dulls Taste for Sweets
4. Free will takes flight: how our brains respond to an approaching menace
5. Imaging Software Helps Track, Treat Injured Brains
6. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
7. Rasheda Ali to Join Advisory Board of Brainstorm Cell Therapeutics
8. Sleepless Nights Make for Grumpier Brains
9. Sound training rewires dyslexic childrens brains for reading
10. Training, Experience Can Change How Brains Work
11. Scientists explain how insulin secreting cells maintain their glucose sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Illness often undiscovered and undertreated among the uninsured 3A Harvard study 59784 1Illness often undiscovered and undertreated among the uninsured 3A Harvard study 59784 2FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 1FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 2FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 3FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 4Checkered history of mother and daughter cells explains cell cycle differences 10424 1Checkered history of mother and daughter cells explains cell cycle differences 10424 2Checkered history of mother and daughter cells explains cell cycle differences 10424 3